Recent investigational advances in the management of relapsed/refractory myeloma

Paul Richardson

Prof Paul Richardson (Dana-Farber Cancer Institute, Boston, MA) summarises of results of clinical trials in the management of relapsed or refractory multiple myeloma presented at the 2014 American Society of Hematology (ASH) Annual Meeting.

Investigational agents discussed include: proteasome inhibitor, carfilzomib; anti-CD38 monoclonal antibody, daratumumab: anti-SLAMF7 monoclonal antibody, elotuzumab; histone deacetylase (HDAC) inhibitor, panobinostat; HDAC6 inhibitor, ricolinostat; immunomodulatory agent, pomalidomide.

Share this video  
Similar topics
Related videos
1:19
Moving towards a daratumumab standard of care in MM
Meletios Dimopoulos
1:44
OPTIMISMM: benefits of a new triplet therapy for MM patients relapsing on lenalidomide
Meletios Dimopoulos
2:43
Imaging modalities and treatment breakthroughs in myeloma bone disease
Meletios Dimopoulos
4:35
Cereblon pathway-mediated IMiD resistance in multiple myeloma
Constantine Mitsiades
3:38
Anti-BCMA CAR T-cells in myeloma: what data do we have so far?
Yi Lin
Multiple Myeloma
Antibodies, Carfilzomib, Daratumumab, Elotuzumab, Panobinostat, Pomalidomide, Ricolinostat
ASH 2014
Interview
6th December 2014
More from Paul Richardson
A multiple myeloma patient story - a discussion between Vivien de Gunzburg and Paul Richardson
Defibrotide: still early days but a promising outlook for veno-occlusive disease
Recent drug approvals for the treatment of relapsed/refractory multiple myeloma
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals